Abstract: The present application relates to the field of treatment of diseases, and in particular, to an anti-CLDN18.2 antibody or an antigen-binding fragment thereof, nucleic acid molecules for encoding said antibody and fragment, and method for preparing said antibody and fragment. The anti-CLDN18.2 antibody or the antigen-binding fragment thereof has high specificity and affinity to CLDN18.2, and can effectively bind to CLDN18.2 and mediate the killing of CLDN18.2 expressing cells. Therefore, the present application further relates to a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof, and use thereof in the preparation of drugs, wherein the drugs are used for the prevention and/or treatment of tumors.

Abstract: The present invention relates to the field of treatment of diseases and immunology. Specifically, the present invention relates to an anti-LAG-3 antibody or an antigen-binding fragment thereof, nucleic acid molecules for encoding said antibody and fragment, and method for preparing said antibody and fragment. The anti-LAG-3 antibody or the antigen-binding fragment thereof according to the present invention has high specificity and high affinity to LAG-3, can effectively block the binding of LAG-3 to MHC II and/or FGL1, and can inhibit and/or block intracellular signaling mediated by LAG-3 binding to MHC II and/or FGL1. Therefore, the present invention further relates to a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof, and use of the pharmaceutical composition in the preparation of drugs.

Abstract: In certain aspects, a semiconductor device includes a first semiconductor layer, a first semiconductor structure formed on the first semiconductor layer including a main chip region, and seal ring discontinuous contact structures formed in a seal ring region enclosing the main chip region. Each seal ring discontinuous contact structure includes a seal ring body portion and a through silicon contact (TSC) portion penetrating through the first semiconductor layer and coupled to the seal ring body portion.

Abstract: The present disclosure provides an exciter and an electronic product. The exciter comprises: a magnetic circuit assembly comprising a first housing and a magnet, and the magnet is connected to the first housing; a coil assembly comprising a second housing and a coil, and the coil is disposed in a magnetic field formed by the magnet, wherein the coil assembly is configured to be capable of generating a vibration relative to the magnetic circuit assembly, the coil is formed by winding a wire having a polygonal cross section. According to the present disclosure, the coil wire has a polygonal cross section, so that an interval between the wires can be reduced in the wound coil, the number of turns of the coil is increased in the same space, the effective length of the coil is increased, and the driving force generated from the coil is increased.

Abstract: Embodiments of this application relate to the field of terminal technologies, and describe a method for displaying a dynamic image and a terminal, which resolve a problem that power consumption of a terminal caused by an existing method in which three-dimensional real-time rendering is used is relatively high. The method may be applied to a terminal, and can includes obtaining, from a video file based on a preset factor, a plurality of pieces of image frame data in a one-to-one correspondence to a plurality of image frames. The method may also include decoding the plurality of pieces of image frame data, to obtain the plurality of image frames. Furthermore, the method can include successively displaying the plurality of image frames obtained through the decoding, to present the dynamic image.

Abstract: Related are an anti-TSLP antibody or an antigen-binding fragment thereof, nucleic acid molecules coding the same, and a method for preparing the same. The anti-TSLP antibody or the antigen-binding fragment thereof have high affinity to TSLP, capable of effectively binding with TSLP and blocking the proliferative effect of TSLP with respect to Ba/F3-hTSLPR-hIL7R? cells, and blocking the capability of TSLP in activating and secreting cytokines with respect to PBMC. At the same time, further related are a medicinal composition comprising the antibody or the antigen-binding fragment thereof, and uses of the composition in preparing a medicament for preventing and/or treating asthma, allergic inflammation, an allergic reaction or autoimmune disease.

Abstract: Embodiments of this application relate to the field of terminal technologies, and describe a method for displaying a dynamic image and a terminal, which resolve a problem that power consumption of a terminal caused by an existing method in which three-dimensional real-time rendering is used is relatively high. The method may be applied to a terminal, and can includes obtaining, from a video file based on a preset factor, a plurality of pieces of image frame data in a one-to-one correspondence to a plurality of image frames. The method may also include decoding the plurality of pieces of image frame data, to obtain the plurality of image frames. Furthermore, the method can include successively displaying the plurality of image frames obtained through the decoding, to present the dynamic image. The dynamic image includes the plurality of image frames, and the preset factor includes at least one of the following factors: a time point and orientation data.

Abstract: A semiconductor device and a fabricating method thereof are provided. The semiconductor device includes a semiconductor structure and an input/output pad. The semiconductor structure includes a first substrate and a conductive layer, in which the first substrate has a first surface and a second surface opposite to each other, the conductive layer is disposed on the first surface of the first substrate, and the conductive layer includes one or more first trace. The first semiconductor structure has a recess penetrating the first substrate and exposing the one or more first trace, and the input/output pad is disposed on the one or more first trace and in the recess.

Abstract: Aspects of the disclosure provide a semiconductor device. The semiconductor device includes a first die and a second die boned face-to-face. The first die includes first transistors formed on a face side of the first die in a semiconductor portion and at least a contact structure disposed in an insulating portion outside the semiconductor portion. The second die includes a substrate and second transistors formed on a face side of the second die. Further, the semiconductor device includes a first pad structure disposed on a back side of the first die and the first pad structure is conductively coupled with the contact structure. An end of the contact structure protrudes from the insulating portion into the first pad structure. Further, in some embodiments, the semiconductor device includes a connection structure disposed on the back side of the first die and conductively connected with the semiconductor portion.

Abstract: Provided are a recombinant bispecific antibody against CTLA-4 and PDL-1, a nucleic acid molecule for encoding the antibody, a vector and a host cell comprising the nucleic acid molecule, and a method for preparing the antibody. Also provided are a pharmaceutical composition comprising the bispecific antibody, and usage of the bispecific antibody in preparation of the pharmaceutical composition.

Abstract: Provided are a humanized anti-A? monoclonal antibody and use thereof. The humanized anti-A? monoclonal antibody provided can inhibit the polymerization of A? monomers, protect nerve cells from the toxicity of A?, and have a certain effect on improving the cognitive learning and memory ability of Alzheimer's dementia model mice, and can be used for the treatment and diagnosis of diseases and disorders related to amyloidosis, such as Alzheimer's disease.

Abstract: The present disclosure provides a method of fabricating a semiconductor device. The method can include bonding a first die and a second die face to face, the first die including a substrate, transistors formed on a face side of the first die over a semiconductor layer with an insulating layer between the substrate and the semiconductor layer, and a first contact structure on the face side of the first die extending through the insulating layer. The method can also include exposing the first contact structure from the back side of the first die, forming, from the back side of the first die, a contact hole in the insulating layer to expose the semiconductor layer, and forming, on the back side of the first die, a first pad-out structure connected with the first contact structure and a second pad-out structure, on the contact hole, conductively connected with the semiconductor layer.

Abstract: Provided are a composition and the uses thereof. Said composition comprises Megamonas funimormis and/or a metabolite thereof, as well as Anaerofustis stercorihominis and/or a metabolite thereof. Said composition can efficiently treat and prevent inflammation, specifically ulcerative colitis, and related diseases thereof by using a combination of Megamonas funimormis and Anaerofustis stercorihominis, and is safe, efficient, exhibits low toxicity and does not easily produce resistance.

Abstract: Three-dimensional (3D) NAND memory devices and methods are provided. In one aspect, a fabrication method includes preparing a stacked device having a first array device and a second array device, forming an opening on a back side of the second array device, and forming one or more contact pads in the opening. The first array device includes first front pads on a face side of the first array device and first back pads on a back side of the first array device. The second array device includes second front pads on a face side of the second array device and bonded with the first back pads. The one or more contact pads are disposed at a level proximate to the second front pads with respect to the first array device.

Abstract: A memory device includes a memory array, disposed on a substrate of a peripheral-circuit structure; a conductive plug, extending through the memory array and connected to the peripheral-circuit structure; and a conductive pad layer, disposed over the memory array and including a plurality of conductive pads spaced apart from each other. The conductive plug protrudes into a corresponding conductive pad of the plurality of conductive pads.

Abstract: An optical imaging system, along an optical axis from an object side to an image side, sequentially includes: a stop; a first lens having a refractive power; a second lens having a positive refractive power; a third lens having a positive refractive power, an object-side surface and an image-side surface of the third lens being convex surfaces; a fourth lens having a refractive power, and an image-side surface of the fourth lens being a convex surface; a fifth lens having a refractive power, and an image-side surface of the fifth lens being a concave surface; a sixth lens having a refractive power; and a seventh lens having a refractive power. A half of a maximum field-of-view Semi-FOV of the optical imaging system satisfies: Semi-FOV?6°; and a total effective focal length f of the optical imaging system satisfies: f?25 mm.

Abstract: The present invention relates to the field of therapeutic monoclonal antibodies, and specifically provides an anti-FXI/FXIa antibody or an antigen-binding fragment thereof, nucleic acid molecules encoding same, and methods for preparing same. The anti-FXI/FXIa antibody or antigen-binding fragment thereof described in the present invention has specificity and high affinity to FXI/FXIa, and can effectively inhibit the activity of FXI/FXIa. Therefore, the present invention further provides a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof, and a use thereof in the preparation of a drug which is used for the prevention and/or treatment of diseases or disorders related to coagulation or thromboembolism.

Abstract: Provided is a use of Butyribacter intestini in preventing and/or treating inflammation-related diseases. Specifically, in the present disclosure, it was firstly discovered that Butyribacter intestini has the function of preventing and/or treating inflammation-related diseases (for example, inflammatory bowel disease, such as ulcerative colitis, gastritis, and common enteritis; and rheumatoid arthritis).

Abstract: An anti-CD47 monoclonal antibody and use thereof. The provided anti-CD47 monoclonal antibody can effectively inhibit tumor growth. Blocking human SIRP and human CD47 signals may enhance macrophage phagocytosis of tumor cells, prevent the tumor cells from escaping a tumor immune defense system, and have an anti-tumor function. Blocking association between the CD47 on a tumor cell surface and the SIRP on a macrophage surface may block a “do not eat me” signal from the tumor cells, promoting tumor cell recognition and uptake of macrophages, and thereby facilitating tumor cells to be phagocytosed. The association between the CD47 on a tumor cell surface and the SIRP on a macrophage surface is a common “do not eat me” signal. The anti-CD47 antibody, as a very promising target in the tumor immune system, will play a powerful and effective role in human cancer therapy.

Abstract: The present invention discloses an application of Bacteroides cellulosilyticus in preparing a preparation for preventing and/or treating lipid metabolism related diseases, such as atherosclerosis related diseases, cardiovascular diseases and obesity.